Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
AssigneeIo Therapeutics, Inc.
InventorsRoshantha A. Chandraratna, Martin E. Sanders
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods for treating cancer comprising administering at least one immune checkpoint inhibitor and at least one Retinoic Acid Receptor or Retinoid X Receptor active agent.
Claims18
A method of treating cancer comprising administering at least one immune checkpoint inhibitor, wherein the immune checkpoint inhibitor comprises an antibody specific for at least one of CTLA-4, PD-1, TIM-3, LAG-3, PD-L1, B7-H3, B7-H4, BTLA, ICOS, or OX40, and one or more means for potentiating activity of the immune checkpoint inhibitor to promote a T cell mediated immune response and wherein said means comprise a Retinoic Acid Receptor (RAR)¥ selective agonist.
Dependencies are inferred from the claim text.